<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The aim of the study was to try thrombo ASS in combined therapy of patients with <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS), to evaluate its efficacy in prevention of recurrent vascular defects </plain></SENT>
<SENT sid="1" pm="."><plain>Thrombo ASS tablets (50-100 mg) were included in combined treatment of 45 patients with APS (6 males and 39 females, mean age 36.1 +/- 11.7 years, mean APS duration 10.2 +/- 9.0 years) and 8 patients with SLE (1 male and 7 females) matched for age </plain></SENT>
<SENT sid="2" pm="."><plain>Antiphospholipin antibodies and clinical status were assessed before treatment and after the treatment within 9 months </plain></SENT>
<SENT sid="3" pm="."><plain>It was found that addition of thrombo ASS to combined treatment of APS improves coagulation and microcirculation due to effective muscular blood flow, increases number of platelets in peripheral blood </plain></SENT>
<SENT sid="4" pm="."><plain>Tablets covered with coating resistant to gastric juice reduce frequency of gastric side effects </plain></SENT>
</text></document>